Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

BTX-1188 Demonstrates Safety Benefits, Enters Phase 1 Trials in AML and Solid Tumors

June 4th 2022

BTX-1188, a first-in-class oral molecular glue, is undergoing investigation in phase 1 clinical trials in patients with solid tumors or acute myeloid leukemia, after preclinical trials supported its potential safety benefits in this population and demonstrated its high sensitivity in Myc-driven cancer cell lines.

Epcoritamab Plus R-CHOP Shows Efficacy and Tolerability as First-Line Treatment for High-Risk DLBCL

June 4th 2022

The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line treatment of patients with high-risk diffuse large B-cell lymphoma according to updated results of a single-arm of the EPCORE NHL-2 trial.

Hyper-CVAD Plus Sequential Blinatumomab With or Without Inotuzumab Elicits Clinical Benefit in Ph-Negative B-Cell ALL

June 4th 2022

Sequential administration of blinatumomab with or without inotuzumab following hyper-CVAD elicited high rates of minimal residual disease negativity and a durable overall survival benefit among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic lymphoma.

Addition of Ivosidenib to Azacitidine Improves Outcomes in Newly Diagnosed IDH1-Mutant AML

June 4th 2022

The combination of ivosidenib and azacitidine elicited a clinically meaningful benefit across end points compared with azacitidine alone among patients with newly diagnosed IDH1-mutant acute myeloid leukemia who were ineligible for intensive induction chemotherapy.

Glofitamab Demonstrates Durable Response in Heavily Pretreated Large B-Cell Lymphoma

June 4th 2022

Glofitamab elicited an objective response rate of 51.6% when administered for a fixed duration among patients with patients with heavily pretreated, highly refractory large B-cell lymphoma, regardless of prior CAR T-cell therapy exposure, according to findings from a phase 2 expansion study.

Frontline Brentuximab Vedotin Plus Chemotherapy Improves 6-Year Survival in Hodgkin Lymphoma

June 3rd 2022

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine demonstrated a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, with a manageable safety profile consistent with prior findings in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma

June 3rd 2022

Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.

Rolling Submission of BLA to FDA Completed for Omidubicel in Blood Cancers Requiring Transplant

June 2nd 2022

The rolling biologics license application submission to the FDA to support the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant has been completed.

Selecting the Right Patients for CPX-351 or Venetoclax + Azacitidine in AML

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, provide an overview of how patients with AML are selected for treatment with CPX-351 or the combination of venetoclax-azacitidine.

CPX-351 in Treatment of AML and Clinical Considerations

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, comment on the role of CPX-351 in the treatment of secondary AML and offer practice pointers for treatment with this drug, including management of adverse events.

FDA Withdraws Approvals for Umbralisib in MZL, Follicular Lymphoma Due to Safety Concerns

June 1st 2022

The FDA announced that it has withdrawn approval for umbralisib, an oral inhibitor of PI3K-δ and CK1-ε manufactured by TG Therapeutics.

Dr. Sallman on the Novel Menin Inhibitor KO-539 in AML

May 31st 2022

David Sallman, MD, discusses the background of the menin inhibitor, KO-539, in acute myeloid leukemia.

Sorafenib Plus Standard Chemotherapy Provides Clinical Benefit in Pediatric FLT3-ITD+ AML

May 30th 2022

The addition of sorafenib to conventional chemotherapy was safe and demonstrated evidence of improved outcomes in pediatric patients with FLT3-ITD–positive acute myeloid leukemia.

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

May 27th 2022

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Zanubrutinib Approved in Uruguay for MCL, MZL, and Waldenström Macroglobulinemia

May 27th 2022

The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.

Patient Profile 1: Patient with Secondary Acute Myeloid Leukemia

May 26th 2022

Two experts review a patient profile and discuss whether the patient meets the criteria for secondary acute myeloid leukemia (AML).

Secondary Acute Myeloid Leukemia (AML): Overview

May 26th 2022

Richard Stone, MD, and Eunice Wang, MD, define secondary acute myeloid leukemia treatment goals and how treatment has been affected by the COVID-19 pandemic.

FDA Approves Ivosidenib Plus Azacitidine for Newly Diagnosed IDH1-Mutated AML

May 25th 2022

The FDA has approved ivosidenib (Tibsovo) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

FDA Lifts Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept Plus Pembrolizumab in Advanced Malignancies

May 24th 2022

The FDA has lifted a partial clinical hold on the phase 1 NEON-2 trial investigating the use of davoceticept in combination with pembrolizumab in adult patients with advanced solid tumors or lymphoma.

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia

May 20th 2022

The FDA has approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.